|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0023981,
umls-concept:C0029246,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0239307,
umls-concept:C0338344,
umls-concept:C0684249,
umls-concept:C0871261,
umls-concept:C1257890,
umls-concept:C1513882,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:dateCreated |
2002-11-14
|
|
pubmed:abstractText |
Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:author |
pubmed-author:BezjakAndreaA,
pubmed-author:DebruyneChannaC,
pubmed-author:GiacconeGiuseppeG,
pubmed-author:HirshVeraV,
pubmed-author:KrzakowskiMaciejM,
pubmed-author:LamontAlanA,
pubmed-author:MartinsHeidiH,
pubmed-author:RubinSheldonS,
pubmed-author:SaduraAnnaA,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrances AFA,
pubmed-author:SmylieMichaelM,
pubmed-author:ZeeBennyB
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4434-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:articleTitle |
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
|
|
pubmed:affiliation |
National Cancer Institute of Canada-Clinical Trials Group. frances.shepherd@uhn.on.ca
|
